REVB 8‑K: Item 2.02 press release, Exhibit 99.1 Q3 2025

Rhea-AI Filing Summary

Revelation Biosciences, Inc. furnished an 8‑K announcing it issued a press release with financial results for the three and nine months ended September 30, 2025.

The release is included as Exhibit 99.1 under Item 2.02 and will not be treated as “filed” or incorporated by reference unless expressly stated.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001810560false0001810560us-gaap:CommonStockMember2025-11-062025-11-060001810560revb:RedeemableWarrantsEachExercisableForA150400ThShareOfCommonStockAtAnExercisePriceOf579600PerShareMember2025-11-062025-11-0600018105602025-11-062025-11-06

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 06, 2025

REVELATION BIOSCIENCES, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-39603	84-3898466
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
4660 La Jolla Village Drive Suite 100
San Diego, California				92122
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (650) 800-3717

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.001 per share		REVB		The Nasdaq Stock Market LLC
Redeemable warrants, each exercisable for a 1/50,400th share of common stock at an exercise price of $579,600 per share		REVBW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 6, 2025, Revelation Biosciences, Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1.

The information in Item 2.02 and in Exhibit 99.1 will not be treated as “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or into another filing under the Exchange Act, unless that filing expressly incorporates this information by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press release, dated November 6, 2025
104		Cover Page Interactive Data File (embedded with the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		REVELATION BIOSCIENCES, INC.
Date: November 6, 2025	By:	/s/ Chester S. Zygmont, III
		Chester S. Zygmont, III Chief Financial Officer (principal financial and accounting officer)

FAQ

What did REVB disclose in this 8‑K?

The company furnished a press release announcing financial results for the three and nine months ended September 30, 2025, included as Exhibit 99.1 under Item 2.02.

Which period do the REVB results cover?

The press release covers the three and nine months ended September 30, 2025.

Is the information considered 'filed' under Section 18?

No. The Item 2.02 information and Exhibit 99.1 are furnished, not filed, and are not incorporated by reference unless expressly stated.

Where can I find the detailed results for REVB?

See Exhibit 99.1 to the 8‑K, which contains the full press release with financial results.

What exhibits are included with this REVB 8‑K?

The filing includes Exhibit 99.1 (press release dated November 6, 2025) and Exhibit 104 (Cover Page Inline XBRL).

On which exchange do REVB securities trade and what are the tickers?

Common stock trades on Nasdaq under REVB; redeemable warrants trade on Nasdaq under REVBW.

What is the description of REVB’s listed warrants?

Redeemable warrants, each exercisable for a 1/50,400th share of common stock at an exercise price of $579,600 per share.